Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Bladder Cancer

Free Subscription 06.04.2026 1 ACS Omega 1 Acta Cytol 1 Actas Urol Esp (Engl Ed) 1 Anal Chem 4 Anticancer Res 1 Biol Direct 1 Biomater Adv 1 Bioorg Chem 1 Biosensors (Basel) 2 BJU Int 2 BMC Cancer 1 BMC Urol 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Imaging 1 Cancer Med 1 Cancer Metab 4 Cancers (Basel) 1 Cardiovasc Interv Ther 1 Cell Death Differ 1 Chin Med J (Engl) 1 Clin Exp Med 1 Clin Genitourin Cancer 3 Curr Oncol 3 Curr Opin Urol 1 Eur Radiol 1 Expert Rev Anticancer Ther 3 Front Immunol 1 Front Med (Lausanne) 2 Front Oncol 1 Front Pharmacol 1 Front Urol 1 Gene 1 Hinyokika Kiyo 1 In Vitro Cell Dev Biol Anim 1 Indian J Pathol Microbiol 1 Infect Drug Resist 2 Int J Mol Sci 2 Int J Urol 1 J Cancer Res Ther 2 J Exp Clin Cancer Res 1 J Mol Cell Biol 1 J Mol Histol 2 J Natl Compr Canc Netw 1 J Pathol Clin Res 1 Jpn J Radiol 1 Lasers Med Sci 1 medRxiv 1 Mol Med Rep 1 Mol Pharm 1 Nurs Open 1 Oncol Rep 2 Oncol Res 1 Oncol Rev 1 PLoS One 1 Radiol Med 1 Res Rep Urol 2 Sci Rep 1 Semin Oncol 1 Urol Int 1 Urol Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

ACS Omega

1. WANG Q, Wang H, Lan P, Yang B, et al
   Integrative Transcriptomics, Machine Learning, and Molecular Dynamics Reveal Honghua Longdan (Gentiana rhodantha)?Modulated Therapeutic Targets in Bladder Cancer.
   ACS Omega. 2026;11:17996-18009.
   PubMed         Abstract available
   
   

   
   Acta Cytol

2. XIONG L, Li J, Jin X, Cao X, et al
   An Artificial Intelligence-Based Method for Risk Stratification of Urothelial Carcinoma from Liquid-Based Urine Cytology Whole-Slide Images.
   Acta Cytol. 2026;70:211-222.
   PubMed         Abstract available
   
   

   
   Actas Urol Esp (Engl Ed)

3. GUEDES OLIVA P, Jimenez Marrero P, Espino Espino R, Marrero Dominguez R, et al
   Urachal adenocarcinoma: Case report, literature review, and therapeutic algorithm proposal.
   Actas Urol Esp (Engl Ed). 2026;50:501916.
   PubMed         Abstract available
   
   

   
   Anal Chem

4. YUAN Y, Xie T, Hu X, Wei X, et al
   Aptamer-Based Discovery of Neuropilin-2 as a Potential Biomarker and Therapeutic Target in Bladder Cancer.
   Anal Chem. 2026 Mar 31. doi: 10.1021/acs.analchem.5c07494.
   PubMed         Abstract available
   
   

   
   Anticancer Res

5. SATO T, Sano T, Adachi H, Ikeda Y, et al
   Clinicopathological Characteristics and Clinical Course of Non-muscle-invasive Bladder Cancer Secondary to Radical Nephroureterectomy.
   Anticancer Res. 2026;46:2077-2086.
   PubMed         Abstract available
   
   
6. SUGIYAMA Y, Naiki T, Morikawa T, Odagiri K, et al
   Prognostic Impact of Early GNRI Sustainability in Metastatic Urothelial Carcinoma Receiving Pembrolizumab.
   Anticancer Res. 2026;46:2187-2198.
   PubMed         Abstract available
   
   
7. LIAO CH, Chang WS, Chang SY, Wang YC, et al
   Insights From Matrix Metalloproteinase-2 Genotypes to Decipher the Genetic Architecture of Bladder Cancer Risk.
   Anticancer Res. 2026;46:1861-1874.
   PubMed         Abstract available
   
   
8. GUTIU AG, Marrah AJ, Voss BB, Cowan BC, et al
   Allow Aloe to Do the Work: Aloe vera Constrains Growth of Bladder Cancer Cells and Modulates Expression of Key Costimulatory Molecules.
   Anticancer Res. 2026;46:1883-1892.
   PubMed         Abstract available
   
   

   
   Biol Direct

9. SPEZIALE R, Iacovelli V, Leoni G, Anzillotti L, et al
   Plasma metabolomic profiling identifies a metabolic signature for non-muscle-invasive bladder cancer independent of hematuria.
   Biol Direct. 2026 Apr 3. doi: 10.1186/s13062-026-00766.
   PubMed         Abstract available
   
   

   
   Biomater Adv

10. LIU X, Chen L, Lin L, Xie Y, et al
    PLZ4@SeD-induced ferroptosis sensitizes bladder cancer to chemotherapy and immunotherapy.
    Biomater Adv. 2026;185:214842.
    PubMed         Abstract available
    
    

    
    Bioorg Chem

11. GRUBA N, Stachurski L, Lesner A
    Utility of FRET substrates in bladder cancer diagnosis.
    Bioorg Chem. 2026;175:109818.
    PubMed         Abstract available
    
    

    
    Biosensors (Basel)

12. HAO Z, Yue S, Yao L, Gong Y, et al
    Non-Invasive Urine-Based Diagnostic Technologies for Early Bladder Cancer.
    Biosensors (Basel). 2026;16:171.
    PubMed         Abstract available
    
    

    
    BJU Int

13. HJORT PB, Jensen JB, Ernst A
    Long-term outcomes following a 5-year recurrence-free interval in non-muscle-invasive bladder cancer.
    BJU Int. 2026 Mar 28. doi: 10.1111/bju.70267.
    PubMed         Abstract available
    
    
14. SIVA J, Aydogdu C, Heller N, Jonnalagadda R, et al
    Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach.
    BJU Int. 2026 Apr 2. doi: 10.1111/bju.70269.
    PubMed         Abstract available
    
    

    
    BMC Cancer

15. TANUMA K, Shiga M, Sano K, Hamada K, et al
    Systemic administration of liposomal trehalose dimycolate induces NK1.1(+) cell mediated antitumor immunity in bladder cancer.
    BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15951.
    PubMed        
    
    
16. KIM JH, Maeng S, Choi J, Lee CU, et al
    The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guerin and an anti-PD-1 inhibitor in bladder cancer.
    BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15890.
    PubMed        
    
    

    
    BMC Urol

17. LUO J, Cheng Z, Chen L, Li X, et al
    Correlation analysis of HER2 expression with clinicopathological features and prognosis based on data from 444 patients with urothelial carcinoma.
    BMC Urol. 2026;26:86.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

18. PRADO S, Ugge H, Vikerfors A, Fall K, et al
    Anti-Inflammatory Diet Index (AIDI) and Bladder Cancer Risk by Stage: A 22-Year Prospective Swedish Cohort Study (1998-2020).
    Cancer Epidemiol Biomarkers Prev. 2026.
    PubMed         Abstract available
    
    

    
    Cancer Imaging

19. ZHANG Y, Cai L, Chen Y, Bai R, et al
    MRI based unsuperviced clustering on MIBC reveals intratumor heterogeneity phenotypes and neoadjuvant chemotherapy efficacy.
    Cancer Imaging. 2026;26:48.
    PubMed         Abstract available
    
    

    
    Cancer Med

20. GOKHALE P, Zapata LV
    Immune-Related Adverse Events in Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors: Insights From a FAERS Disproportionality Analysis.
    Cancer Med. 2026;15:e71777.
    PubMed         Abstract available
    
    

    
    Cancer Metab

21. KAMAL AHM, Putluri V, Gandhi T, Ambati CSR, et al
    Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer.
    Cancer Metab. 2026;14:8.
    PubMed         Abstract available
    
    

    
    Cancers (Basel)

22. NTOUMAS GN, Kougioumtzopoulou A, Desse D, Fragkoulis C, et al
    Bladder Preservation with Concurrent Chemoradiotherapy Following Complete Response to Induction Systemic Therapy in Patients with Muscle-Invasive Bladder Cancer: A Review of the Existing Literature.
    Cancers (Basel). 2026;18:961.
    PubMed         Abstract available
    
    
23. KIM DK, Jeon J, Kwon JK, Bang S, et al
    Efficacy and Toxicity in Scheduled Intravesical Gemcitabine Versus Bacillus Calmette-Guerin for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Cancers (Basel). 2026;18:990.
    PubMed         Abstract available
    
    
24. LILLESAND M, Austdal M, Mroz J, Skaland I, et al
    Spatial Immune Profiling and AI-Based Classifiers Identify Predictors of BCG Therapy Outcomes in High-Risk Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2026;18:938.
    PubMed         Abstract available
    
    
25. UGRINOVSKI D, Saidi S, Stankov V, Ambardjieva M, et al
    Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer.
    Cancers (Basel). 2026;18:1026.
    PubMed         Abstract available
    
    

    
    Cardiovasc Interv Ther

26. KUSUMOTO H, Inoue M, Shishikura D, Kanzaki Y, et al
    Myocardial infarction due to nonbacterial thrombotic endocarditis in a patient with advanced bladder cancer.
    Cardiovasc Interv Ther. 2026 Mar 31. doi: 10.1007/s12928-026-01256.
    PubMed        
    
    

    
    Cell Death Differ

27. HUA X, Huang M, Deng X, Xu J, et al
    Correction: The inhibitory effect of compound ChlA-F on human bladder cancer cell invasion can be attributed to its blockage of SOX2 protein.
    Cell Death Differ. 2026 Apr 2. doi: 10.1038/s41418-026-01721.
    PubMed        
    
    

    
    Chin Med J (Engl)

28. OU J, Ni K, Song H, Li G, et al
    The hidden burden: Clinical impact of incidental prostate cancer in bladder cancer patients.
    Chin Med J (Engl). 2026 Mar 30. doi: 10.1097/CM9.0000000000004031.
    PubMed        
    
    

    
    Clin Exp Med

29. CAO Y, Li C, Hua Y, Wu T, et al
    Multi-omics identification of a programmed cell death-related signature and potential target P4HB for bladder cancer based on a 101-combination machine learning and experimental validation.
    Clin Exp Med. 2026;26:214.
    PubMed        
    
    

    
    Clin Genitourin Cancer

30. RIVES H, Fredette J, Anari F, Ghatalia P, et al
    Assessing Treatment Outcomes of Patients Undergoing Enfortumab Vedotin Dose Reduction in Metastatic Bladder Cancer.
    Clin Genitourin Cancer. 2026 Mar 3:102525. doi: 10.1016/j.clgc.2026.102525.
    PubMed         Abstract available
    
    

    
    Curr Oncol

31. SOUTH N, Mihai IM, Wang V, Agoumi M, et al
    Urachal Signet Ring Cell Carcinoma: A Clinicopathological Analysis of 28 Cases.
    Curr Oncol. 2026;33:153.
    PubMed         Abstract available
    
    
32. VENTO J, Zhang T, Lotan Y, Woldu S, et al
    Novel Immune Checkpoint Inhibitor and Antibody-Drug Conjugate Approaches in the Perioperative Management of Muscle-Invasive Bladder Cancer.
    Curr Oncol. 2026;33:162.
    PubMed         Abstract available
    
    
33. MARWAHA A, Sambhi R, Fernandes R
    Dermatomyositis as a Paraneoplastic Syndrome of Metastatic Urothelial Carcinoma.
    Curr Oncol. 2026;33:176.
    PubMed         Abstract available
    
    

    
    Curr Opin Urol

34. ALIAGA A, Avila C, Fernandez MI
    Navigating bladder preservation in Bacillus Calmette-Guerin-unresponsive disease: how much risk is too much?
    Curr Opin Urol. 2026;36:235-243.
    PubMed         Abstract available
    
    
35. AHMAD A, Lepiarczyk O, Birtle AJ
    Personalised medicine in urothelial carcinoma: where do we stand and what is the way to go?
    Curr Opin Urol. 2026;36:250-256.
    PubMed         Abstract available
    
    
36. LEE YHA, Wong CM, Liu AQ, Teoh JY, et al
    The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.
    Curr Opin Urol. 2026;36:244-249.
    PubMed         Abstract available
    
    

    
    Eur Radiol

37. BONATTI M, Valletta R, D'Erme L, Dolciami M, et al
    Preoperative staging of cervical cancer: time to shift from cystoscopy to MRI.
    Eur Radiol. 2025 Oct 4. doi: 10.1007/s00330-025-12039.
    PubMed         Abstract available
    
    

    
    Expert Rev Anticancer Ther

38. ZHANG Y, Yan R, Wang H, Man J, et al
    From macroscopic clearance to molecular eradication: paradigm shift and future perspectives in the detecting of residual lesions after transurethral resection of bladder tumors.
    Expert Rev Anticancer Ther. 2026;26:463-477.
    PubMed         Abstract available
    
    

    
    Front Immunol

39. OLUWATOLA O, Bazargan S, Irrera P, Chang D, et al
    Transdermal bicarbonate buffer therapy increases intratumoral pH and elicits antitumor responses in bladder cancer.
    Front Immunol. 2026;17:1706250.
    PubMed         Abstract available
    
    
40. AVILA-NIETO C, Jung G, Salih HR, Hagelstein I, et al
    Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.
    Front Immunol. 2026;17:1794705.
    PubMed         Abstract available
    
    
41. KNEZEVIC M, Tomaskovic I, Murgic J, Vrhovec B, et al
    Immune landscape of muscle-invasive bladder cancer: role of TIGIT, LAG-3, and PD-L1.
    Front Immunol. 2026;17:1777409.
    PubMed         Abstract available
    
    

    
    Front Med (Lausanne)

42. URSO L, Feletti F, Lancia F, Canella F, et al
    Diagnostic accuracy of (18)F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study.
    Front Med (Lausanne). 2026;13:1792243.
    PubMed         Abstract available
    
    

    
    Front Oncol

43. RUSSO F, Tripodi L, Caldora F, Pandolfo SD, et al
    Identification of a weighted urinary microbial signature for bladder cancer discrimination.
    Front Oncol. 2026;16:1784501.
    PubMed         Abstract available
    
    
44. LIU R, Wang J
    Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives.
    Front Oncol. 2026;16:1786965.
    PubMed         Abstract available
    
    

    
    Front Pharmacol

45. ZHUANG J, Wang H, Chen Z, Wang J, et al
    Baicalin chemosensitivity enhancement of cisplatin in bladder cancer via autophagy flux inhibition.
    Front Pharmacol. 2026;17:1676788.
    PubMed         Abstract available
    
    

    
    Front Urol

46. SHIBAMORI K, Hashimoto K, Okabe K, Maehana T, et al
    Absence of bladder cancer cells in surgical smoke from robot-assisted radical cystectomy: a prospective study.
    Front Urol. 2026;6:1714844.
    PubMed         Abstract available
    
    

    
    Gene

47. BOILLAT S, Goasmat V, Derre L, Domingos-Pereira S, et al
    Corrigendum to "Role of myeloid-derived suppressor cells in bladder cancer and targeted therapeutic strategies" [Gene 970 (2025) 149772].
    Gene. 2026 Mar 28:150129. doi: 10.1016/j.gene.2026.150129.
    PubMed        
    
    

    
    Hinyokika Kiyo

48. SATO T, Hayata N, Hida T, Miura T, et al
    [A Case of Asymptomatic Paraganglioma of the Bladder].
    Hinyokika Kiyo. 2026;72:1-6.
    PubMed         Abstract available
    
    

    
    In Vitro Cell Dev Biol Anim

49. YI L, Chen Q, Zeng M, Xiao Z, et al
    Elevated intravesical pressure promotes circulating tumor cell release in an orthotopic mouse model of bladder cancer.
    In Vitro Cell Dev Biol Anim. 2026 Mar 30. doi: 10.1007/s11626-026-01176.
    PubMed         Abstract available
    
    

    
    Indian J Pathol Microbiol

50. TRIPATHY SR, Ayyanar P, Das DK, Barik SK, et al
    Plasmacytoid subtype of urothelial carcinoma - Report of two rare cases and unusual features.
    Indian J Pathol Microbiol. 2026;69:174-177.
    PubMed         Abstract available
    
    

    
    Infect Drug Resist

51. YAN YC, Guo Q, Xu J, Wei Z, et al
    Marked Non-Infectious Elevation of Procalcitonin in a Hemodialysis Patient with Bladder Cancer: A Case Report.
    Infect Drug Resist. 2026;19:569356.
    PubMed         Abstract available
    
    

    
    Int J Mol Sci

52. SINGH SP, Liu R, Yan F, Tang Q, et al
    Galactokinase 1 Inhibition-Induced Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells Is Associated with AKT Signaling Downregulation.
    Int J Mol Sci. 2026;27:2911.
    PubMed         Abstract available
    
    
53. BAI J, Yu H, Hu C, Ma Y, et al
    Integrating Multi-Omics Atlas to Uncover Genetic and Epigenetic Mechanisms and Reveal Cell State Evolution Across Ecotypes in Male Urological Cancers.
    Int J Mol Sci. 2026;27:2712.
    PubMed         Abstract available
    
    

    
    Int J Urol

54. USUI A, Hara T, Oka S, Sakaguchi K, et al
    Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With Non-Muscle Invasive Bladder Cancer: Real-World Incidence and Concomitant Medication Effects.
    Int J Urol. 2026;33:e70448.
    PubMed         Abstract available
    
    
55. FUJITA N
    Editorial Comments to "Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care".
    Int J Urol. 2026;33:e70452.
    PubMed        
    
    

    
    J Cancer Res Ther

56. JHA T, Ahuja A, Sharma M, Goel HK, et al
    Uncommon but aggressive: A case series on urinary bladder neuroendocrine carcinomas.
    J Cancer Res Ther. 2026;22:196-199.
    PubMed         Abstract available
    
    

    
    J Exp Clin Cancer Res

57. HE Y, Gong Y, Wu Y, He S, et al
    RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated regulation of ZO2.
    J Exp Clin Cancer Res. 2026 Mar 30. doi: 10.1186/s13046-026-03684.
    PubMed        
    
    
58. FRASCOLLA C, Mastroianni R, Macedo-Silva C, De Menna M, et al
    Bridging phenotype and function in bladder cancer using immuno-competent organoids and ex vivo drug screening.
    J Exp Clin Cancer Res. 2026 Apr 1. doi: 10.1186/s13046-026-03701.
    PubMed        
    
    

    
    J Mol Cell Biol

59. XIAO Y, Yang J, Sun M, Li Y, et al
    The tumor-associated fibroblasts regulate urothelial carcinoma progression.
    J Mol Cell Biol. 2026;17:mjaf032.
    PubMed         Abstract available
    
    

    
    J Mol Histol

60. CHI Q, Xu H, Li H, Ma G, et al
    Cx43 modulates malignant phenotypes in bladder cancer cells via the c-Src/PTEN/FAK axis.
    J Mol Histol. 2026;57:129.
    PubMed         Abstract available
    
    

    
    J Natl Compr Canc Netw

61. OTANI Y, Otani K, Rodden D, Lemieux M, et al
    PCO26-275: Single Cell RNA-seq of Circulating Tumor Cells in Recurrent Bladder Cancer After Bladder-Sparing Trimodality Therapy.
    J Natl Compr Canc Netw. 2026;24.
    PubMed        
    
    
62. SU ZT, Florissi IS, Geller AE, Johnson Iii BA, et al
    Cost-Effectiveness of Perioperative Durvalumab With Neoadjuvant Gemcitabine/Cisplatin in Muscle-Invasive Bladder Cancer Treatment.
    J Natl Compr Canc Netw. 2026 Mar 19:1-7. doi: 10.6004/jnccn.2025.7129.
    PubMed         Abstract available
    
    

    
    J Pathol Clin Res

63. OLAH C, Juhasz D, Varadi M, Reis H, et al
    Molecular subtype concordance and metastatic patterns in muscle-invasive bladder cancer.
    J Pathol Clin Res. 2026;12:e70088.
    PubMed         Abstract available
    
    

    
    Jpn J Radiol

64. XIAO W, Zhang Z, Wang Y, Zhang W, et al
    Enhancing the performance of BP-MRI VI-RADS in detecting muscle-invasive bladder cancer: the potential role of supplementary quantitative parameters.
    Jpn J Radiol. 2026 Mar 27. doi: 10.1007/s11604-026-01970.
    PubMed         Abstract available
    
    

    
    Lasers Med Sci

65. CHEN D, Zhou Z, Wei G, Zhang F, et al
    Perioperative and oncological outcomes of thulium laser-ERBT versus conventional TURBT in non-muscle invasive bladder cancer: a meta-analysis of 2,934 patients.
    Lasers Med Sci. 2026;41:63.
    PubMed         Abstract available
    
    

    
    medRxiv

66. MAGNANI CJ, D'Andrea VD, Barros GG, Qian Z, et al
    Clinical and genomic profiling of early-onset bladder cancer identifies key alterations and therapeutic targets.
    medRxiv [Preprint]. 2026 Mar 24:2025.01.10.25320337.
    PubMed         Abstract available
    
    

    
    Mol Med Rep

67. QIAO Q, Guo R, Sun Z, Shi Y, et al
    Polyphyllin II regulates ROS levels and promotes ferroptosis in bladder cancer cells.
    Mol Med Rep. 2026;33:148.
    PubMed         Abstract available
    
    

    
    Mol Pharm

68. DURRANI FA, Cacaccio J, Potter W, Dukh M, et al
    Anticancer Efficacy of HPPH-PDT Synergies with BCG-Immunotherapy or COX-2 Inhibitor in Treating Bladder Cancer.
    Mol Pharm. 2026 Apr 1. doi: 10.1021/acs.molpharmaceut.5c01678.
    PubMed         Abstract available
    
    

    
    Nurs Open

69. ZHOU L, Chen Y, Yuan X, Guo F, et al
    Experiential Aspects in Patients With Permanent Urostomy Following Bladder Cancer Surgery: Meta-Synthesis of Qualitative Studies.
    Nurs Open. 2026;13:e70517.
    PubMed         Abstract available
    
    

    
    Oncol Rep

70. WANG X, Chen E, Yang X, Wang Y, et al
    [Expression of Concern] 5?Azacytidine inhibits the proliferation of bladder cancer cells via reversal of the aberrant hypermethylation of the hepaCAM gene.
    Oncol Rep. 2026;55:103.
    PubMed         Abstract available
    
    

    
    Oncol Res

71. GIORGIONE R, Grasso D, Gambale E, Scolari F, et al
    Serum Biomarkers in Bladder Cancer: NMR Metabolomics for Identification and Monitoring during Platinum-Based Therapy.
    Oncol Res. 2026;34:1.
    PubMed         Abstract available
    
    
72. SUN S, Zhang J, Zheng Z, Hao Y, et al
    PSMD2-Mediated MAPK Signaling Promotes Bladder Cancer Development and Immune Microenvironment Remodeling.
    Oncol Res. 2026;34:30.
    PubMed         Abstract available
    
    

    
    Oncol Rev

73. YI X, Zhao Z, Li J
    Development and validation of a risk prediction model for chemical cystitis in patients with non-muscle-invasive bladder cancer undergoing intravesical instillation.
    Oncol Rev. 2026;20:1791893.
    PubMed         Abstract available
    
    

    
    PLoS One

74. CHEN J, Li B, Gan Y, Li P, et al
    TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer.
    PLoS One. 2026;21:e0346131.
    PubMed         Abstract available
    
    

    
    Radiol Med

75. BORRELLI A, Novelli S, Messina E, Laschena L, et al
    AI-assessed sarcopenia as an independent predictor of neoadjuvant chemotherapy outcomes in muscle-invasive bladder cancer.
    Radiol Med. 2026 Mar 31. doi: 10.1007/s11547-026-02203.
    PubMed         Abstract available
    
    

    
    Res Rep Urol

76. HEMMATI GHAVSHOUGH M, Fu MZ, Islam R, Patel D, et al
    Sequential Intravesical Gemcitabine and Docetaxel for Non-Muscle Invasive Bladder Cancer: A Narrative Review Across Risk Groups.
    Res Rep Urol. 2026;18:584499.
    PubMed         Abstract available
    
    

    
    Sci Rep

77. GUO X, Wang S, Ma Y, Chen Y, et al
    Efficacy and safety of RC48 alone or combined with PD-1 inhibitors in high-risk non-muscle invasive bladder cancer.
    Sci Rep. 2026 Apr 2. doi: 10.1038/s41598-026-43393.
    PubMed        
    
    
78. KABUS M, Aumiller M, Ruhm A, Pongratz T, et al
    Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells.
    Sci Rep. 2026;16:11228.
    PubMed         Abstract available
    
    

    
    Semin Oncol

79. LIU Y, Zhao T, Shi R, Xie Y, et al
    Cancer-associated fibroblasts in bladder cancer: Immunosuppressive mechanisms and therapeutic targeting.
    Semin Oncol. 2026;53:152483.
    PubMed         Abstract available
    
    

    
    Urol Int

80. WANG Q, Lin Q, Li L, Wei W, et al
    The Predictive Value of Urinary Twist1 Methylation and VI-RADS Score for Residual Tumor before Repeat Transurethral Resection of Bladder Tumor in NMIBC Patients.
    Urol Int. 2026;110:114-124.
    PubMed         Abstract available
    
    

    
    Urol Oncol

81. PATEL KN, Yalla P, Panchal H, Pandya SJ, et al
    Is complete TURBT mandatory before radical cystectomy in cases of muscle-invasive bladder cancer?
    Urol Oncol. 2026 Mar 28:111080. doi: 10.1016/j.urolonc.2026.111080.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum